Abstract：Objective: To investigate the impact and predictive value of serum biomarkers and clinical characteristics on stroke recurrence in patients with high-risk non-disabling ischemic cerebrovascular events (HR-NICE) patients. Methods: A total of 105 patients with high-risk non-disabling ischemic stroke from February 2022 to February 2024 were enrolled and divided into two groups according to recurrence status: recurrence group (24 cases) and non-recurrence group (81 cases). Serum biomarker levels, clinical characteristics and follow-up data were collected. Univariate and multivariate analyses were used to identify factors influencing recurrence and ROC curves were employed to evaluate their predictive value. Results: Among the 105 patients, the recurrence rate was 22.86%. Compared with the non-recurrence group, the proportion of diabetic patients and the levels of hs-CRP, sCD 40L, Lp-PLA2 and Hcy were significantly elevated in the recurrence group(P<0.05). Multivariate Logistic regression analysis showed that hs-CRP [OR (95% CI) = 2.697 (1.410~5.157)], sCD 40L [OR (95% CI) = 15.029 (3.120~72.408)], and Hcy [OR (95% CI) = 1.966 (1.126~3.434)] were independent risk factors for stroke recurrence in HR-NICE patients, with P values all <0.05. The combined ROC curve for hs-CRP, sCD 40L, and Hcy showed an AUC (95% CI) of 0.982 (0.960~1.000), with a sensitivity of 96.3% and a specificity of 91.7%. Conclusion: hs-CRP, sCD 40L and Hcy are risk factors for stroke recurrence in HR-NICE patients. Monitoring these biomarkers provides valuable predictive information for assessing the prognosis of HR-NICE patients.
董晶晶, 许辉, 涂峰, 张孟恩. 高危非致残性缺血性脑血管事件复发的患者影响因素及其预测价值分析[J]. 河北医学, 2026, 32(1): 112-116.
DONG Jingjing, XU Hui, TU Feng, et al. Analysis of the Influencing Factors and Predictive Value of Stroke Recurrence in High-risk Non-Disabling Ischemic Cerebrovascular Events Patients. HeBei Med, 2026, 32(1): 112-116.
[1] Tu W J,Wang L D.China stroke surveillance report 2021[J].Mil Med Res,2023,10(1):33. [2] Li S,Jing J,Li J,et al.Elevated hs-CRP and symptomatic intracranial/extracranial artery stenosis predict stroke recurrence after acute ischemic stroke or TIA[J].Atheroscler Thromb,2023,30(6):601-610. [3] Wang K,Hong T,Liu W,et al.Development and validation of a machine learning-based prognostic risk stratification model for acute ischemic stroke[J].Sci Rep,2023,13(1):13782. [4] 王名丽,陈蕊,刘晓莉,等.高危非致残缺血性脑血管事件抗血小板治疗的研究进展[J].临床神经病学杂志,2024,37(5):379-383. [5] Li Z A,Gao Y,Han L,et al.HR-MRI-based nomogram network calculator to predict stroke recurrence in high-risk non-disabling ischemic cerebrovascular events patients[J].Front Neurol,2024,15(1):1407516. [6] Attiq A,Afzal S,Ahmad W,et al.Hegemony of inflammation in atherosclerosis and coronary artery disease[J].Eur Pharmacol,2024,966(1):176338. [7] Li J,Pan Y,Wang M,et al.Predictive role of hsCRP in recurrent stroke differed according to severity of cerebrovascular disease:analysis from a prospective cohort study[J].Clin Med,2023,12(4):1676. [8] 王俊波,武彦霞,郭丹丹,等.血清sCD 40L和Galectin-3对急性缺血性脑卒中患者治疗效果及预后的预测价值[J].检验医学与临床,2024,21(16):2422-2426. [9] Angeli F,Verdecchia P,Savonitto S,et al.Soluble CD40 ligand and outcome in patients with coronary artery disease undergoing percutaneous coronary intervention[J].Clin Chem Lab Med,2022,60(1):118-126. [10] Prasad K.Atherogenic effect of homocysteine,a biomarker of inflammation and its treatment[J].Int Angiol,2024,33(4):262-270. [11] Li W,Ding Z,Rong L,et al.A one-year relapse prediction model for acute ischemic stroke (AIS) based on clinical big data[J].Heliyon,2024,10(11):32176.
2026, Vol. 32 
冀公网安备13080202000786号